Literature DB >> 12885235

Fibrillar aggregates of the tumor suppressor p53 core domain.

Daniella Ishimaru1, Leonardo R Andrade, Luciano S P Teixeira, Pablo A Quesado, Larissa M Maiolino, Priscila M Lopez, Yraima Cordeiro, Lilian T Costa, Wolfgang M Heckl, Gilberto Weissmüller, Debora Foguel, Jerson L Silva.   

Abstract

Alzheimer's disease, Parkinson's disease, cystic fibrosis, prion diseases, and many types of cancer are considered to be protein conformation diseases. Most of them are also known as amyloidogenic diseases due to the occurrence of pathological accumulation of insoluble aggregates with fibrillar conformation. Some neuroblastomas, carcinomas, and myelomas show an abnormal accumulation of the wild-type tumor suppressor protein p53 either in the cytoplasm or in the nucleus of the cell. Here we show that the wild-type p53 core domain (p53C) can form fibrillar aggregates after mild perturbation. Gentle denaturation of p53C by pressure induces fibrillar aggregates, as shown by electron and atomic force microscopies, by binding of thioflavin T, and by circular dichroism. On the other hand, heat denaturation produced granular-shaped aggregates. Annular aggregates similar to those found in the early aggregation stages of alpha-synuclein and amyloid-beta were also observed by atomic force microscopy immediately after pressure treatment. Annular and fibrillar aggregates of p53C were toxic to cells, as shown by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] reduction assay. Interestingly, the hot-spot mutant R248Q underwent similar aggregation behavior when perturbed by pressure or high temperature. Fibrillar aggregates of p53C contribute to the loss of function of p53 and seed the accumulation of conformationally altered protein in some cancerous cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12885235     DOI: 10.1021/bi034218k

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  70 in total

1.  Reversible aggregation plays a crucial role on the folding landscape of p53 core domain.

Authors:  Daniella Ishimaru; Luis M T R Lima; Lenize F Maia; Priscila M Lopez; Ana P Ano Bom; Ana P Valente; Jerson L Silva
Journal:  Biophys J       Date:  2004-08-06       Impact factor: 4.033

2.  Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway.

Authors:  Ricardo E Perez; Chad D Knights; Geetaram Sahu; Jason Catania; Vamsi K Kolukula; Daniel Stoler; Adolf Graessmann; Vasily Ogryzko; Michael Pishvaian; Christopher Albanese; Maria Laura Avantaggiati
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

3.  Evidence of a Prion-Like Transmission of p53 Amyloid in Saccharomyces cerevisiae.

Authors:  Shinjinee Sengupta; Samir K Maji; Santanu K Ghosh
Journal:  Mol Cell Biol       Date:  2017-08-28       Impact factor: 4.272

4.  Role of the undergraduate student research assistant in the new millennium.

Authors:  Thais Dutra Nascimento Silva; Lúcia Cristina da Cunha Aguiar; Jaqueline Leta; Dilvani Oliveira Santos; Fernanda Serpa Cardoso; Lúcio Mendes Cabral; Carlos Rangel Rodrigues; Helena Carla Castro
Journal:  Cell Biol Educ       Date:  2004

5.  Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.

Authors:  Rui Kamada; Takao Nomura; Carl W Anderson; Kazuyasu Sakaguchi
Journal:  J Biol Chem       Date:  2010-10-26       Impact factor: 5.157

Review 6.  Thermodynamic and functional characteristics of deep-sea enzymes revealed by pressure effects.

Authors:  Eiji Ohmae; Yurina Miyashita; Chiaki Kato
Journal:  Extremophiles       Date:  2013-09       Impact factor: 2.395

7.  p53 protein aggregation promotes platinum resistance in ovarian cancer.

Authors:  Y Yang-Hartwich; M G Soteras; Z P Lin; J Holmberg; N Sumi; V Craveiro; M Liang; E Romanoff; J Bingham; F Garofalo; A Alvero; G Mor
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

8.  p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.

Authors:  Luciana P Rangel; Giulia D S Ferretti; Caroline L Costa; Sarah M M V Andrade; Renato S Carvalho; Danielly C F Costa; Jerson L Silva
Journal:  J Biol Chem       Date:  2019-01-02       Impact factor: 5.157

9.  Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function.

Authors:  L Palanikumar; Laura Karpauskaite; Mohamed Al-Sayegh; Ibrahim Chehade; Maheen Alam; Sarah Hassan; Debabrata Maity; Liaqat Ali; Mona Kalmouni; Yamanappa Hunashal; Jemil Ahmed; Tatiana Houhou; Shake Karapetyan; Zackary Falls; Ram Samudrala; Renu Pasricha; Gennaro Esposito; Ahmed J Afzal; Andrew D Hamilton; Sunil Kumar; Mazin Magzoub
Journal:  Nat Commun       Date:  2021-06-25       Impact factor: 14.919

10.  The p53 core domain is a molten globule at low pH: functional implications of a partially unfolded structure.

Authors:  Ana Paula D Ano Bom; Monica S Freitas; Flavia S Moreira; Danielly Ferraz; Daniel Sanches; Andre M O Gomes; Ana Paula Valente; Yraima Cordeiro; Jerson L Silva
Journal:  J Biol Chem       Date:  2009-11-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.